The Natalie Warren Bryant Community Clinical Oncology Program (NWBCCOP) is a single component, community-based cancer research organization, based on the structure of the 10- year NCI-funded Cancer Center and its parent institute, Saint Francis Hospital (SFH) in Tulsa. Saint Francis Hospital is the largest provider of cancer care in the Tulsa SMSA with 36.3 percent of all its area's inpatient hospitalization and 32.0 percent of all outpatient care. Its catchment area includes all of northeastern Oklahoma and adjacent areas of Kansas, Missouri, and Arkansas. The 1985 population was about 1.4 million. The program has been commended as the largest accruer of patients in the ECOG Community Hospital Program. The Operations Office headquarters is on site at the Natalie Warren Bryant Cancer Center (NWBCC) and SFH serves as the fiscal agent. The program has established affiliation agreements with ECOG for the past 10 years and has long been implementing centralized data management, quality control and reporting functions. Thirteen physician investigators participate and are responsible for over 1,500 new cancer patients annually. Over the past 10 years, the program has entered 1,016 patients on ECOG protocols alone with recent averages of 80 to 100 patients annually. A recent cancer control and treatment research base affiliation has been formed with M. D. Anderson. The program projects a Year 01 rate of 101 ECOG accrual credits, and 31 MDA accrual credits for treatment protocols. Cancer control accrual credits are projected to be 68.0. Community cancer control experience is strong, including CGOP operations, numerous previous protocol studies with CALGB, ECOG and institutional studies, pilot studies, pain management, hemocult screenings, breast screening, professional and patient education programs.
Witte, R S; Lipsitz, S; Goodman, T L et al. (1999) A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest New Drugs 17:173-7 |
Wiernik, P H; Greenwald, E S; Ball, H et al. (1998) High-dose megestrol acetate in the treatment of patients with ovarian cancer who have undergone previous treatment: Eastern Cooperative Oncology Group Study PD884. Am J Clin Oncol 21:565-7 |